Earnings Releases·Nov 2, 2026, 4:12 PM ET

Bioventus — Third Quarter 2026 Earnings Summary

Q3 2026 worldwide revenue rose 3% year-over-year to $142.4 million, while net income and non-GAAP EPS increased to $6.0 million and $0.17 respectively, driven by lower interest expense and strong volume in Pain Treatments.
Full-year 2026 net sales guidance was updated to $590–$595 million (4–5% growth), while Adjusted EPS guidance was reaffirmed at $0.75–$0.79 and Adjusted Cash from Operations guidance set at $84–$89 million.
The company executed a $15.0 million discretionary principal prepayment on its term loan, reducing long-term debt to $211.1 million, though cash and cash equivalents declined to $30.7 million.
Management continues to review potential strategic alternatives to maximize shareholder value, noting that this process may divert attention and incur costs, while regulatory risks regarding FDA reclassification of EXOGEN and hyaluronic acid products persist.